Products
Cimicoxib is commercially available in the form of chewable tablets for dogs (Cimalgex). It has been approved in many countries since 2011.
Structure and properties
Cimicoxib (C16H13ClFN3O3S, Mr = 381.8 g/mol) is a chlorinated and fluorinated benzenesulfonamide and imidazole derivative. It has a V-shaped structure like other COX-2 inhibitors, which allows binding to the Active Site of the enzyme.
Effects
Cimicoxib (ATCvet QM01AH93) is analgesic, antipyretic, and anti-inflammatory. Its properties are based on selective and potent inhibition of the enzyme cyclooxygenase-2 (COX-2). In clinical trials, it showed comparable effects to firocoxib and carprofen.
Indications
For the treatment of pain and inflammation associated with osteoarthritis and for perioperative pain management in orthopedic and soft tissue surgery in dogs. Cimicoxib is not approved as a human drug. Clinical trials are underway to determine whether it is suitable for the treatment of depression and schizophrenia in humans.
Dosage
According to the SmPC. Dose is based on body weight and administered once daily with or without food. Individuals should wash their hands after handling the tablets.
Contraindications
Cimicoxib is contraindicated in hypersensitivity, dogs less than 10 weeks of age, gastrointestinal or hemorrhagic disease, in combination with glucocorticoids, NSAIDs, in breeding animals, pregnant or lactating bitches. For complete precautions, see the drug label.
Interactions
Concomitant use of glucocorticoids and nonsteroidal anti-inflammatory drugs is not recommended because they may increase adverse effects.
Adverse effects
The most common possible adverse effects include digestive symptoms such as vomiting and diarrhea. Rarely, severe reactions such as ulcers and bleeding are possible. Increases in renal biochemical parameters have been reported. Other COX-2 inhibitors such as rofecoxib (Vioxx, off label) are known to increase the risk of cardiovascular disease.
